Cerluten vs Epithalon

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Epithalon is believed to activate telomerase, the enzyme responsible for maintaining telomere length, with several in vitro and animal studies reporting telomere elongation. It also appears to regulate the expression of p53 and other cell-cycle control genes, modulate the hypothalamic-pituitary axis via pineal gland activity, and upregulate antioxidant defences including superoxide dismutase and catalase.

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm regulation and telomerase activity in aging cells, and to exert broad anti-aging effects through epigenetic gene expression modulation in pineal and other tissues. Epithalon is proposed to activate telomerase and modulate telomere maintenance in aging somatic cells, normalize melatonin production and the neuroendocrine-immune axis, and restore physiological parameters that decline with aging; in vitro studies and preclinical animal models provide mechanistic support for these effects. Published human studies from the Khavinson group include a controlled clinical trial demonstrating epithalon's effects on retinal function in retinitis pigmentosa patients and observational data showing melatonin rhythm normalization in elderly subjects, representing the strongest indexed clinical evidence specifically for epithalon; both studies are formally indexed in PubMed. Epithalon has no FDA approval and no approved indication in any Western jurisdiction; published clinical evidence derives from a single research group without external independent replication by standard Western trial methodology, and while the mechanistic and observational research is indexed in peer-reviewed journals, the evidence base does not meet the threshold for established efficacy in any recognized clinical condition. Epithalon dosage protocols: no human clinical trial has established a standardized dosing regimen for epithalon. The published Khavinson clinical research does not report specific dose-response data in a format translatable to general dosing guidance. Research protocols and anecdotal bodybuilding and anti-aging community practice commonly reference epithalon at doses of 5–10mg per injection administered subcutaneously, with course lengths of 10–20 consecutive daily injections repeated one to two times per year — a pattern derived from the animal research and the Khavinson group's general bioregulator protocol framework, not from a dose-ranging clinical trial. Intranasal delivery has also been explored due to direct CNS access via the olfactory pathway. Epithalon is a research compound with no approved clinical dosing guidelines in any jurisdiction; all dosing references reflect preclinical and anecdotal research contexts only.